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Abstract
Introduction: In light of the prospective Prenatal Assess-
ment of Genomes and Exomes (PAGE) study, this paper 
aimed to determine the additional costs of using exome se-
quencing (ES) alongside or in place of chromosomal micro-
array (CMA) in a fetus with an identified congenital anomaly. 
Methods: A decision tree was populated using data from a 
prospective cohort of women undergoing invasive diagnos-
tic testing. Four testing strategies were evaluated: CMA, ES, 
CMA followed by ES (“stepwise”); CMA and ES combined. Re-
sults: When ES is priced at GBP 2,100 (EUR 2,407/USD 2,694), 
performing ES alone prenatally would cost a further GBP 
31,410 (EUR 36,001/USD 40,289) per additional genetic diag-
nosis, whereas the stepwise would cost a further GBP 24,657 
(EUR 28,261/USD 31,627) per additional genetic diagnosis. 
When ES is priced at GBP 966 (EUR 1,107/USD 1,239), per-
forming ES alone prenatally would cost a further GBP 11,532 
(EUR 13,217/USD 14,792) per additional genetic diagnosis, 
whereas the stepwise would cost a further additional GBP 
11,639 (EUR 13,340/USD 14,929) per additional genetic diag-
nosis. The sub-group analysis suggests that performing 
stepwise on cases indicative of multiple anomalies at ultra-
sound scan (USS) compared to cases indicative of a single 
anomaly, is more cost-effective compared to using ES alone. 
Discussion/Conclusion: Performing ES alongside CMA is 
more cost-effective than ES alone, which can potentially lead 
to improvements in pregnancy management. The direct ef-
fects of test results on pregnancy outcomes were not exam-
ined; therefore, further research is recommended to exam-
ine changes on the projected incremental cost-effectiveness 
ratios. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Structural anomalies can be identified prenatally in 3% 
of pregnancies using ultrasound scan (USS) [1]. They can 
occur de novo or secondary to chromosomal abnormali-
ties (a change in the structure or number of chromosomes 
in the DNA) or single gene abnormalities (a mutation in 
a single gene) that may contribute to long-term disabil-
ities and are associated with a risk of perinatal mortali- 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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ty and morbidity. Data collected by the National Congeni-
tal Anomaly and Rare Disease Registration Service 
(NCARDRS) and summarised by the Department of 
Health (2018) found that in 2016, 205 per 10,000 births 
were associated with one or more congenital anomaly [2]. 
It is therefore highly relevant to identify cases prenatally 
to better understand the genetic aetiology of congenital 
anomalies and to improve individualised pregnancy 
management. 
Prenatal fetal chromosomal analysis is used to detect 
the most common causes of congenital anomaly and pro-
vides a diagnosis in up to 40% of cases [3]. Such analysis 
can be performed on samples obtained invasively (i.e., 
chorionic villus sampling or amniocentesis). Once a fetal 
DNA sample has been collected, some chromosomal ab-
normalities may be examined by quantitative fluorescent 
polymerase chain reaction (QF-PCR) and/or chromo-
somal microarray (CMA) [4, 5]. Many healthcare sys-
tems, such as many regions of the UK, use CMA as a sup-
plement to QF-PCR following a normal genetic diagnosis 
(where a congenital anomaly has not been identified), 
whilst some countries (i.e., Belgium) use CMA as a first 
tier for prenatal indications [6, 7]. Recent studies have 
found CMA alone to be more effective compared to QF-
PCR alone and other conventional testing techniques 
(e.g., karyotype), with CMA detecting approximately 
3–7% more anomalies [8, 9].
Exome sequencing (ES) is a next-generation technol-
ogy assay that is able to detect single nucleotide variants 
that are associated with monogenic disorders (disorders 
caused by a mutation in a single gene) [10, 11]. In our re-
cently published prospective multicentre study from the 
UK, using prenatal ES in fetuses with structural anoma-
lies on ultrasound found that anomalies were identified 
in 52/610 cases (8.5; 95% CI 6.4–11.0%) and a further 24 
cases (3.9%) were identified as variant of uncertain sig-
nificance (VUS) with potential clinical utility [12]. This 
potentially allows better prognostic prediction; including 
the prediction of recurrence risks.
ES is an additional health economic expense as for op-
timal diagnostic yield trio samples (fetus, mother, and fa-
ther) are required. Nonetheless, given the increased de-
tection rate for monogenic disorders, the technique is ex-
pected to improve individualised pregnancy management 
through the better understanding of genetic aetiology of 
congenital anomalies caused by variants in a single gene.
This paper explores the cost-effectiveness of identify-
ing an additional abnormality, prenatally, by including 
trio ES to currently applied methods, including QF-PCR 
and CMA. 
Methods
A model-based economic analysis was conducted alongside the 
Prenatal Assessment of Genomes and Exomes (PAGE) Study in 
order to assess the cost-effectiveness of 4 prenatal genetic test strat-
egies. Our analysis was undertaken from a healthcare perspective. 
The outcome was measured as cost per additional genetic diagno-
sis, where it was assumed that each genetic diagnosis was equiva-
lent to the identification of a congenital structural abnormality. A 
decision tree model was utilised given the short time frame of the 
study. The model structure was informed by experts from the Bir-
mingham Women’s Hospital. The model was populated using pa-
tient level data (n = 298) from the prospective clinical study. The 
model was built and analysed using TreeAge Pro 2018 [13]. 
PAGE Study Recruitment
The PAGE study aimed to determine a cost-effective genome 
sequencing assay for improved prenatal genetic diagnosis and in-
dividualised pregnancy management. Methodological details of 
the recruitment process for PAGE have been published elsewhere 
[14]. Briefly, prospective women were counselled for recruitment 
into the PAGE study if they were attending a fetal medicine clinic 
for clinically indicated invasive diagnostic procedures. Women 
were included if they met the following inclusion criteria: (1) un-
dergone prenatal invasive testing following the identification of 
one or more anomalies; (2) received a normal result for aneuploi-
dy following a QF-PCR, conventional karyotyping (G-banding) or 
non-invasive prenatal test; (3) received consent to the PAGE study 
from the partner of the prospective woman. 
Model and Diagnostic Strategies
Four diagnostic strategies were examined for the purpose of 
this model, as follows:
Strategy 1. A CMA test was undertaken following a negative 
QF-PCR result. A positive result was indicative of a pathogenic 
finding; a negative finding indicated a normal result. 
Strategy 2. An ES test was undertaken following a negative QF-
PCR result. A positive ES was indicative of a pathogenic finding, 
whilst a negative finding indicated a normal result.
Strategy 3. A CMA test was undertaken following a negative 
QF-PCR result. If the CMA result was negative, then ES testing was 
undertaken. This stepwise approach was the “as per protocol” 
strategy in the PAGE study. The Evaluation of Array Comparative 
genomic Hybridisation (EACH) study noted that CMA had a 
“sample receipt to report” duration of 15 days (IQR 12–25) [9]. 
Recent data from the Baylor College in Texas have noted that for 
ES, an average “turnaround time” (TAT) for initial reporting (ex-
cluding tissue culture time) is 14 days [15]. This model assumed 
the TAT for CMA was 14 days and the TAT for ES was an addi-
tional 21 days. This implies that the TAT for the stepwise was 35 
days. Therefore, when comparing the stepwise pathway to ES 
alone, the former had a slower TAT. 
Strategy 4. A CMA and ES tests were undertaken at the same 
time following a negative QF-PCR result. CMA results were con-
sidered likely to be available before the ES results. 
The model structure is presented in online supplementary Fig-
ure S1 (see www.karger.com/doi/10.1159/000504976 for all online 
suppl. material). A CMA and ES tests were undertaken for all pa-
tients included in the model. For strategies involving only 1 test, 
patients were reallocated to branches as if the missing test was neg-
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ative. The test results of the patients also defined the distribution 
used to derive the branch probabilities. Note that no separate pa-
rameters are needed for test results in strategies 1 and 2. For ex-
ample, the probability of a positive CMA test in strategy 1 is neces-
sarily equal to the overall probability of a positive CMA test in 
strategies 3 and 4. 
Costs and Resource Data
Resource costs were divided into 2 categories: (1) costs incurred 
from genetic testing; (2) costs incurred from other medical man-
agement. Costs associated with genetic testing included CMA and 
ES. The cost of CMA was GBP 345, which included DNA extrac-
tion. This was obtained from West Midlands Regional Genetics 
Laboratory. The cost of ES was GBP 2,100, which included the cost 
of sequencing trio exome samples. This value was an average of 
costing figures obtained from 2 sources: (1) West Midlands Re-
gional Genetics Laboratory, Birmingham Women’s Hospital, UK 
(GBP 2,500); (2) Department of Genetics, Guy’s and St. Thomas’ 
NHS Foundation Trust, UK (GBP 1,700). The costs for genetic test-
ing included staffing, consumables, administration, capital, bioin-
formatics, storage, reporting, and clinical review panel meetings. 
Costs associated with medical management included pregnan-
cy loss (termination of pregnancy [TOP] and spontaneous loss), 
delivery mode (vaginal delivery [VD], elective caesarean, and 
emergency caesarean), follow-up, and post-partum care costs. 
TOP costs were obtained from the NHS National Tariffs [16]. 
Costs associated with mode of delivery were obtained from the 
Personal Social Services Research Unit (PSSRU) National Tariff 
Payment System and the West Midlands Fetal Medicine Centre, 
Birmingham Women’s Hospital, UK [17]. Follow-up costs were 
only included for those with a positive diagnostic result, as further 
counselling was required. This included 245 min consultations 
with a geneticist, and four 1-h consultations with a specialist mid-
wife. Staffing costs were calculated using the “unit costs for hospi-
tal-based doctors” from the PSSRU [18]. Costs associated with 
post-partum care were provided by the Neonatal Unit, Birming-
ham Women’s Hospital, UK [19]. A gamma distribution for cost 
parameters was fitted to the model (Table 1). All costs are present-
ed in UK Sterling for 2016–2017. See online supplementary Table 
S1 for additional information. 
Outcome Measure
The outcome in this model was measured as one additional ge-
netic diagnosis. This is reported in terms of the incremental cost-
effectiveness ratio (ICER), which indicates the additional cost per 
additional genetic diagnosis. 
Analyses
Two key analyses were undertaken. Analysis 1 (A1) exam-
ined all missing and complete case data (missing data included 
pregnancy outcomes [delivery mode: 13%; live births: 3% (VD 
or caesarean type was not specified); overall: approximately 
16%] and test results [VUS: 17%]). Analysis 2 (A2) analysed 
only the complete cases. An additional exploratory analysis was 
undertaken for each phenotype group (brain, skeletal/limb/spi-
nal, cardiac, abdominal/gastro, nuchal translucency, single 
anomaly and multiple anomalies). The results report findings 
for single and multiple anomalies only. VUS cases were exclud-
ed from the sub-analysis, as the exact anomaly identified was 
unknown.
Assumptions
Assumptions were applied to increase the reliability and valid-
ity of the results. The missing data in A1 included both delivery 
mode (16% missing) and test failure (17% missing). It was there-
fore assumed that missing data were proportionate to the complete 
cases within the dataset. This assumption ensured valid samples 
were not excluded unnecessarily. Furthermore, intrauterine de-
mise, miscarriages, and stillbirths were assumed to be TOP cases, 
as the fetus had died in utero. Additionally, VUS cases that were 
not validated at PAGE clinical review panel meetings were as-
sumed to be negative ES cases, whilst VUS cases that were vali-
dated were assumed to be positive ES cases (as these were consid-
ered to be clinically relevant). ES costs were also assumed to be an 
average of cost data from 2 centres (Table 1). The cost data (Table 
1) were converted and presented in EUR and USD from UK ster-
ling using 2017 conversion rates [20] to provide a wider perspec-
tive and generalisability of findings. However, doing so assumed 
all costing figures to be of equal value across countries, despite be-
ing obtained for a UK setting. 
Table 1. Model parameters for costs
Parameter Mean α β Source
Costs, GBP†
Follow-up cost during pregnancy 646 100 0.1548 PSSRU (2016)
Vaginal delivery 1,775 100 0.0570 PSSRU (2016)
Elective caesarean section 1,775 100 0.0570 PSSRU (2016)
Emergency caesarean section 2,582 100 0.0387 PSSRU (2016)
Termination of pregnancy 730 100 0.1371 NHS national tariffs (2017)
Post-partum care 2,810 100 0.0356 Birmingham Women’s Hospital (2017)
CMA 345 100 0.2899 Birmingham Women’s Hospital (2017) 
ES 2,100 100 0.0476 Birmingham Women’s Hospital; 
Guy’s and St. Thomas’ NHS Foundation Trust (2017)
CMA, chromosomal microarray; ES, exome sequencing. † Gamma distribution has been fitted for parameter. 
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Sensitivity Analysis
A limited deterministic sensitivity analysis (DSA) was per-
formed alongside the analysis. A DSA tests the uncertainty sur-
rounding the model parameters by varying the value of one pa-
rameter whilst maintaining the mean values for all other param-
eters. This means that any diagnostic strategy can become the 
preferred option should one parameter be highly sensitive. The 
following changes were made: (1) The cost of ES was assumed to 
decrease by 50% over time, and the ICERs were assessed at 10% 
decrements. (2) In A1, one scenario assumed all forms of unre-
corded delivery were TOP (as a sample review indicated from our 
annual report that this was the most likely associated outcome 
[the centre was just not informed]). (3) In A1, a separate scenario 
assumed all forms of unrecorded delivery were VD. These choic-
es reflect the fact that it is impossible to predict the pregnancy 
outcome due to the variety of anomalies and the differences in 
prognosis for a fetus. 
A probabilistic sensitivity analysis (PSA) was undertaken to de-
termine the level of uncertainty within the model. A Dirichlet dis-
tribution was used for all probabilities of each possible CMA and 
ES result. The test sensitivities and specificities were inferred from 
the sampled probability sets. A Dirichlet distribution for pregnan-
cy outcome parameters was also fitted to the model. Table 2 pres-
ents the model parameters used within A1. The parameters for A2 
and the subgroup analysis are presented in online supplementary 
Table S2–9. Cost-effectiveness values were derived by simultane-
ously selecting random values from each distribution. 10,000 it-
erations were produced to provide an indication of how the varia-
tion in the test sensitivity and specificity affects the possible values 
of the ICER. A cost-effectiveness acceptability curve (CEAC) was 
then produced to examine the probability of cost-effectiveness per 
test strategy at a given willingness to pay (WTP). In this model, the 
WTP ranged between GBP 0 and GBP 50,000 per additional ge-
netic diagnosis.
Table 2. A1: model parameters
Parameter Mean α n-α Source
Combined distribution*
CMA positive + ES positive 0.0101 3 295 Study data
CMA positive + ES negative 0.0268 8 290 Study data
CMA negative + ES negative 0.8792 262 36 Study data
CMA negative + ES positive 0.0839 25 273 Study data
Pregnancy outcome after positive CMA*
Termination of pregnancy 0.4545 5 6 Study data
Vaginal delivery 0.0909 1 10 Study data
Emergency caesarean section 0.0909 1 10 Study data
Elective caesarean section 0.3636 4 7 Study data
Pregnancy outcome after negative CMA*
Termination of pregnancy 0.3554 102 185 Study data
Vaginal delivery 0.3972 114 173 Study data
Emergency caesarean section 0.1185 34 253 Study data
Elective caesarean section 0.1289 37 250 Study data
Pregnancy outcome after positive ES*
Termination of pregnancy 0.5714 16 12 Study data
Vaginal delivery 0.1786 5 23 Study data
Emergency caesarean section 0.0714 2 26 Study data
Elective caesarean section 0.1786 5 23 Study data
Pregnancy outcome after negative ES*
Termination of pregnancy 0.3370 91 179 Study data
Vaginal delivery 0.4074 110 160 Study data
Emergency caesarean section 0.1222 33 237 Study data
Elective caesarean section 0.1333 36 234 Study data
A beta distribution is a family of continuous probability distributions defined on the interval (0, 1), denoted 
by α and β, where α is the number of successes in a trial and β the number of failures. A positive CMA or ES result 
was indicative of an abnormal diagnosis. A negative CMA or ES result was indicative of normal diagnosis, 
meaning an anomaly was not identified in the fetus. Approximately 12% of all cases were detected to have an 
abnormal diagnosis. Outcome rates were based on cases post-delivery, meaning the test results were communicated 
to the parents at this point. MD, missing data accounted for (analysis one); CMA, chromosomal microarray; ES, 
exome sequencing. (* Dirichlet distribution is a multivariate generalisation of beta distribution.)
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Results
The results for A1 are presented in Table 3 and are ex-
plored within this section of the paper. The results for A2 
have been presented and explained in the online suppl. 
Table S10, 11. In A1, CMA alone (strategy 1) was the least 
costly strategy, with a mean of GBP 3,654 (EUR 4,188/
USD 4,687) per additional genetic diagnosis. 12.08% of all 
cases were identified to have an anomaly. CMA alone 
identified approximately 30% of all positive cases. ES 
alone (strategy 2) was more expensive but detected ap-
proximately 78% of all positive cases (8% of which would 
be solved by CMA alone). Combining the differences in 
overall costs and effects, ES alone costs an additional GBP 
31,410 (EUR 36,001/USD 40,289) per additional genetic 
diagnosis compared to CMA alone.
The stepwise (strategy 3) was more effective and more 
costly than the previous 2 strategies. This is because both 
tests were undertaken on most cases, which enabled it to 
identify all cases with a detectable anomaly. Even so, the 
Table 3. A1: incremental ICERs for the base case and 5 scenario analyses
Strategy Cost, GBP Effectiveness ICER
mean incremental mean incremental
Base case
CMA alone (strategy 1) 3,654 0.0369
ES alone (strategy 2) 5,446 1,792 0.0940 0.0570 31,410
CMA then ES (strategy 3) 5,723 2,069 0.1208 0.0839 24,657
CMA and ES (strategy 4) 5,800 2,146 0.1208 0.0839 25,581
Scenario 1
CMA alone (strategy 1) 3,654 0.0369
ES alone (strategy 2) 5,236 1,582 0.0940 0.0570 27,729
CMA then ES (strategy 3) 5,520 1,866 0.1208 0.0839 22,246
CMA and ES (strategy 4) 5,590 1,936 0.1208 0.0839 23,078
Scenario 2
CMA alone (strategy 1) 3,654 0.0369
ES alone (strategy 2) 5,026 1,372 0.0940 0.0570 24,048
CMA then ES (strategy 3) 5,318 1,664 0.1208 0.0839 19,836
CMA and ES (strategy 4) 5,380 1,726 0.1208 0.0839 20,575
Scenario 3
CMA alone (strategy 1) 3,654 0.0369
ES alone (strategy 2) 4,816 1,162 0.0940 0.0570 20,367
CMA then ES (strategy 3) 5,116 1,462 0.1208 0.0839 17,425
CMA and ES (strategy 4) 5,170 1,516 0.1208 0.0839 18,072
Scenario 4
CMA alone (strategy 1) 3,654 0.0369
ES alone (strategy 2) 4,606 952 0.0940 0.0570 16,685
CMA then ES (strategy 3) 4,914 1,260 0.1208 0.0839 15,014
CMA and ES (strategy 4) 4,960 1,306 0.1208 0.0839 15,568
Scenario 5
CMA alone (strategy 1) 3,654 0.0369
ES alone (strategy 2) 4,396 742 0.0940 0.0570 13,004
CMA then ES (strategy 3) 4,711 1,057 0.1208 0.0839 12,603
CMA and ES (strategy 4) 4,750 1,096 0.1208 0.0839 13,065
Base case: assume ES is GBP 2,100. Scenario 1: Assume ES has decreased by 10% and is therefore GBP 1,890. 
Scenario 2: Assume ES has decreased by 20% and is therefore GBP 1,680. Scenario 3: Assume ES has decreased 
by 30% and is therefore GBP 1,470. Scenario 4: Assume ES has decreased by 40% and is therefore GBP 1,260. 
Scenario 5: Assume ES has decreased by 50% and is therefore GBP 1,050. CMA, chromosomal microarray; ES, 
exome sequencing.
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additional cost per additional genetic diagnosis was GBP 
24,657 (EUR 28,261/USD 31,627) when compared to 
CMA alone. This was lower than ES alone when com-
pared to CMA alone (GBP 31,410 >GBP 24,657 [EUR 
36,001 >EUR 28,261; USD 40,289 >USD 31,627]), mean-
ing the stepwise dominated both strategies. This can be 
seen graphically in Figure 1 and numerically in the online 
supplementary Table S12 and 13. The combined (strategy 
4) was dominated by the stepwise, as it was more costly 
with the same effectiveness (Table 3). These results sug-
gest that CMA is the least costly strategy, but, if the WTP 
is at least GBP 24,657 (EUR 28,261/USD 31,627) per ad-
ditional genetic diagnosis, the stepwise strategy would be 
preferred.
Deterministic Sensitivity Analyses
Five additional scenarios were investigated following 
the base case analysis in A1 (Table 3). Each scenario test-
ed a reduction in the cost of ES of up to 50% by 10% dec-
rements. In each scenario, the pattern of dominance re-
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Co
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Combined CMA and ES
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Fig. 1. A1: Cost-effectiveness analysis, base 
case.
Table 4. A1: Incremental ICERs for the deterministic analyses
Strategy Cost, GBP Effectiveness ICER
mean incremental mean incremental
Cost of ES is GBP 966 (54% reduction in cost)
CMA alone (strategy 1) 3,654 0.0369
ES alone (strategy 2) 4,312 658 0.0940 0.0570 11,532
CMA then ES (strategy 3) 4,630 976 0.1208 0.0839 11,639
CMA and ES (strategy 4) 4,666 1,012 0.1208 0.0839 12,064
Missing outcomes assumed to be VD
CMA alone (strategy 1) 3,830 0.0369
ES alone (strategy 2) 5,622 1,792 0.0940 0.0570 31,410
CMA then ES (strategy 3) 5,894 2,063 0.1208 0.0839 24,595
CMA and ES (strategy 4) 5,971 2,141 0.1208 0.0839 25,519
Missing outcomes assumed to be TOP
CMA alone (strategy 1) 3,328 0.0369
ES alone (strategy 2) 5,120 1,792 0.0940 0.0570 31,410
CMA then ES (strategy 3) 5,394 2,065 0.1208 0.0839 24,619
CMA and ES (strategy 4) 5,471 2,143 0.1208 0.0839 25,543
CMA, chromosomal microarray; ES, exome sequencing; VD, vaginal delivery; TOP, termination of pregnancy.
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mained consistent with the base case analysis. An addi-
tional analysis was therefore undertaken to determine the 
point ES alone became a non-dominated strategy in A1. 
When the cost of ES is reduced to GBP 966 (EUR 1,107/
USD 1,239; 54% reduction) in A1, the ICER for ES alone 
(GBP 11,532 [EUR 13,217/USD 14,792]) becomes lower 
than the stepwise (GBP 11,639 [EUR 13,340/USD 14,929]; 
Table 4). Therefore, ES alone is no longer dominated. A 
change in the assumptions placed on missing pregnancy 
outcome data was also evaluated. The pattern of domi-
nance remained the same as the base case analysis when 
missing data were assumed to be either VD or TOP. See 
Table 4 for further details.
Probabilistic Sensitivity Analysis
The PSA was undertaken to obtain the differences in 
the costs and effectiveness between each strategy in order 
to produce an incremental cost-effectiveness plane. Fig-
ure 2 shows the mean incremental costs and incremental 
effectiveness between CMA alone and ES alone for A1. 
The graph shows a large amount of parameter uncertain-
ty, as the mean incremental costs and incremental effec-
tiveness fall in the north east and the north-west quadrant 
of the plane. This indicates that ES is certain to be more 
costly than CMA, but there is a small probability, consis-
tent with the data available, that ES is also less effective 
than CMA. 
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Figure 3 shows the mean incremental costs and incre-
mental effectiveness between CMA alone and the step-
wise. The graph shows some parameter uncertainty, al-
though all points fall within the north east region of the 
plane. This implies that in all cases the stepwise will iden-
tify more abnormalities than CMA alone, but at an addi-
tional cost. Online supplementary Figure S2 shows the 
mean incremental costs and incremental effectiveness be-
tween ES alone and the stepwise. There is a large amount 
of parameter uncertainty despite all points falling within 
the north east region of the plane. This implies that in all 
cases the stepwise will identify more abnormalities than 
ES alone, but at an additional cost. 
Cost-Effective Acceptability Curves
Figure 4 presents the CEAC for all strategies in A1 
when ES is priced at GBP 2,100 (EUR 2,407/USD 2,694). 
For any possible WTP, the height of each curve shows the 
proportion of model replications at which the relevant 
strategy is cost-effective. The CEAC shows that ES alone 
is very unlikely to be cost-effective at any WTP, while the 
combined is never cost-effective. At a WTP of GBP 30,000 
(EUR 34,385/USD 38,481), the probability that the step-
wise is cost-effective is 78% and the probability that CMA 
alone is cost-effective is 21%. At a WTP of GBP 20,000 
(EUR 22,923/USD 25,654), the probability that the step-
wise is cost-effective is 15%, and the probability that CMA 
alone is cost-effective is 83%. 
Sub-Analysis
The testing strategies identified between 4 and 19% 
of all single and multiple anomalies identified by USS 
(online suppl. Table S14). The ICERs associated with 
ES alone exceeded the ICERs associated with the step-
wise, when compared to CMA alone for both sub-
groups. The stepwise was therefore the optimal strate-
gy. The ICERs associated with the stepwise for each 
subgroup differed by approximately GBP 20,000 (EUR 
22,923/USD 25,654), due to the variation in the incre-
mental cost and effectiveness. The analysis indicated a 
greater diagnostic yield (approximately 7%) and lower 
incremental cost (GBP 58) associated with the multiple 
anomaly subgroup compared to the single anomaly 
subgroup. It is therefore more cost-effective to under-
take the stepwise when the USS is indicative of multiple 
anomalies. 
A PSA was undertaken to derive the CEACs for both 
subgroups, which are presented in online supplementary 
Figure S10 and 11. Multiple anomalies: At WTP thresh-
olds of GBP 20,000 (EUR 22,923/USD 25,654) and GBP 
30,000 (EUR 34,385/USD 38,481), the probability that the 
stepwise is cost-effective exceeds the probability that ei-
ther CMA alone or ES alone are cost-effective. Single 
anomaly: At WTP thresholds of GBP 20,000 (EUR 22,923/
USD 25,654) and GBP 30,000 (EUR 34,385/USD 38,481), 
the probability that CMA alone is cost-effective exceeds 
the probability that either the stepwise or ES alone is cost-
effective. The probability that the stepwise is more cost-
effective compared to either the CMA alone or ES alone 
requires a WTP of at least GBP 35,000 (EUR 40,115/USD 
44,894). Additional details of the analysis are presented in 
online supplementary Table S15. Online supplementary 
Tables S14 and 15 also present the findings for the addi-
tional subgroups analysed.
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Discussion
Main Findings
This paper was built on a study conducted by Hillman 
et al. [8] that explored the cost-effectiveness of CMA 
against conventional prenatal testing techniques (e.g., 
QF-PCR). Comparing findings with Hillman et al. [8] was 
difficult, as the use of ES as a supplement for QF-PCR was 
not explored. Nevertheless, this paper demonstrates that 
prenatal ES alone identifies more abnormalities than 
CMA alone, despite being more costly. This means the 
diagnostic yield for ES alone is greater than CMA alone 
(A1: 78 > 30%; A2: 82 > 26%). From a health economics 
perspective, however, this model suggests ES alone is not 
good value for money when ES costs GBP 2,100 (EUR 
2,407/USD 2,694) in both analyses. This is because the 
additional cost per additional fetal anomaly case genetic 
diagnosis for ES alone exceeds the cost for the stepwise 
(i.e., A1: GBP 31,410 >GBP 24,657 [EUR 36,001 >EUR 
28,261; USD 40,289 >USD 31,627]). Therefore, in the case 
of A1, if the WTP exceeds GBP 31,410 (EUR 36,001/USD 
40,289), the stepwise would still be recommended as its 
resolution is greater and its costs are lower. A similar con-
clusion was made in the sub-analysis for both groups. 
ES alone was likely to be recommended when the cost 
of ES was reduced by 54% (A1), as it was no longer a 
dominated strategy. However, if the WTP were equal to 
the additional cost per additional case solved for the step-
wise, the stepwise would be preferred. The model sug-
gests that solving cases with multiple anomalies would 
likely be more cost-effective compared to solving for cas-
es with single anomalies. This is due to the higher diag-
nostic yield and lower diagnosis cost of ES when solving 
for multiple anomalies. Even so, in each of the above sce-
narios, the direct effect of a test result on a pregnancy 
outcome was not evaluated; therefore, costs outside of a 
study setting might differ. 
If the value of an additional case solved were equal to 
the value of an additional QALY (as defined by the Na-
tional Institute for Health and Care Excellence [NICE]) 
the WTP would fall between GBP 20,000 (EUR 22,923/
USD 25,654; lower threshold) and GBP 30,000 (EUR 
34,385/USD 38,481; upper threshold). This model sug-
gests that in the base case analysis neither the stepwise nor 
ES alone would be recommended at the lower threshold 
value, as the additional cost per genetic diagnosis for both 
strategies exceed GBP 20,000 (EUR 22,923/USD 25,654). 
At GBP 30,000 (EUR 34,385/USD 38,481) the stepwise 
would likely be recommended, as the additional cost per 
additional genetic diagnosis falls below the threshold. 
The model suggests the stepwise would remain the most 
cost-effective strategy at both thresholds when ES is re-
duced either 54%. If multiple anomalies were identified 
by USS, undertaking the stepwise would likely be the 
most cost-effective at either the GBP 20,000 (EUR 22,923/
USD 25,654) or GBP 30,000 (EUR 34,385/USD 38,481) 
threshold, whereas using ES or stepwise for single anom-
alies was not cost-effective at either threshold. Even so, 
the sample size for the multiple anomaly subgroup was 
significantly lower compared to the single anomaly sub-
group, which might have subsequently affected the re-
sults. 
Interpretation
The recent literature recommends CMA for identify-
ing additional anomalies prenatally compared to tech-
niques such as karyotype and QF-PCR, which are still 
used as standard care [5, 7, 21, 22]. This paper suggests 
that ES should also be considered in the testing process, 
as it was able to identify additional anomalies microarray 
was unable to solve. This is especially true for cases with 
multiple anomalies detected by USS, as the model sug-
gests the incremental diagnostic yield is greater and in-
cremental costs are lower compared to cases with single 
anomalies detected by USS. It is recommended that fur-
ther research be undertaken to investigate the efficacy 
and cost-effectiveness of including ES as a supplement for 
CMA (stepwise). This will determine whether findings 
are consistent, and further support the case for imple-
menting ES outside of clinical trial settings [5]. 
Strengths and Limitations 
A strength associated with this paper is the use of pri-
mary data. This provided greater validity to the analysis, 
as the data were collected specifically for the purpose of 
the study. This allowed for inclusion and exclusion crite-
ria to be applied throughout the data collection process 
[13], which enabled the model to present a close depiction 
of reality. This paper also analysed the cost-effectiveness 
of ES per phenotype. To the best of our knowledge, this 
has not been done before. 
There were few caveats to the study. First, in A1, miss-
ing data were assumed to be proportionate to the com-
plete cases. “Live births” were also assumed to be VDs, 
although the delivery mode was not specific (i.e., VD, 
elective caesarean, or emergency caesarean). These as-
sumptions may be incorrect, as it is impossible to predict 
or assume the delivery mode of a pregnancy. The study 
design and ethics approval of the PAGE study prevented 
the disclosure of test results until after pregnancy, mean-
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ing pregnancy outcomes were independent of the results. 
In reality, however, the test diagnosis would be known 
and would likely influence the pregnancy outcome. 
Therefore, the additional cost per genetic diagnosis may 
have been under-/overestimated. Nonetheless, delivery 
mode costs remained in the model to provide an estimate 
of the possible costs incurred to healthcare providers, 
along with an estimate of possible cost-effective strate-
gies. The model evaluated an intermediate outcome, 
meaning the additional costs and effects incurred follow-
ing the birth of a child with an anomaly solved, were not 
explored. Consequently, the additional cost per case 
solved may have been under-/overestimated. 
The model assumed a validated VUS was potentially in-
dicative of a pathogenic and clinically relevant finding, and 
a non-validated VUS was unlikely to be indicative of a clin-
ically relevant finding. This assumption may be incorrect 
given the uncertainty associated with a VUS finding. This 
implies that cases assumed to be clinically relevant may not 
be and vice versa; therefore, affecting the ICERs derived. 
Even so, reporting a VUS result to parents might be inap-
propriate [5]. Therefore, excluding these cases from the 
model could have improved its validity. Hillman et al. [8] 
suggest an effectiveness score be computed when model-
ling VUS cases, but do not discuss computation methods. 
Given that ES has yet become a fully established routine 
clinical diagnostic test, and UK guidance on how and what 
to report is not readily available, the inclusion of VUS cas-
es in this model is further complicated.
The model was unable to explore or quantify the pos-
sible loss/gain of utility to parents once a positive or VUS 
result was reported. The use of QALYs as an outcome mea-
sure was deemed unsuitable. This was due to the difficulty 
associated with counting QALYs when TOP is a possible 
outcome. TOP is the only alternative to delivering a child, 
once a positive or VUS is reported, as treatment following 
a pathogenic finding is generally not possible [6]. This sup-
ports the argument against the use of a QALY. Similar ar-
guments apply to other measures such as the DALY. 
Another limitation was determining whether a strat-
egy was cost-effective. There are no set guidelines defin-
ing the monetary value per genetic diagnosis. To some 
extent, this paper assumed the value of a genetic diagnosis 
to be equivalent to that of a QALY. Using QALY thresh-
olds to determine whether a strategy is cost-effective 
might have therefore been inappropriate. Defined guide-
lines would improve guidance on whether a test strategy 
should be considered. Additionally, the results were re-
ported in EUR and USD. Doing so might have only pro-
vided a numerical estimation for countries using either 
currency, as the healthcare costs are likely to differ be-
tween countries. Finally, the model analysed 298 cases, of 
which only 11 were indicative of being CMA positive. The 
expectation, following discussions with experts in the 
field, was to identify a positive relationship between CMA 
positive and TOP cases. This was not observed. The sam-
ple size might have been too small to depict reality. It is 
recommended that further analyses be undertaken on a 
larger sample size to ensure findings are consistent. 
To conclude, this model suggests that the stepwise is 
the most cost-effective strategy at a WTP of at least GBP 
24,657 (EUR 28,261/USD 31,627). Implementing ES 
alone is only considered when the cost of ES was reduced 
by at least 50%. The findings also suggest that it is more 
cost-effective to analyse cases with multiple anomalies 
identified by USS compared to cases with single anoma-
lies identified by USS. Even so, results should be treated 
with caution as the direct effects of test results on preg-
nancy outcomes were not modelled due to ethical rea-
sons. Therefore, the additional cost per case solved might 
have been over-/underestimated. It is suggested that fur-
ther research be undertaken to investigate this limitation, 
and that a larger sample size be used to improve the valid-
ity and reliability of findings. 
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